Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide. 1999

M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
Department of Internal Medicine I, University of Vienna, Austria.

Treatment options for hepatocellular cancer apart from surgical resection are limited because of the drug-refractory nature of this disease. Little is known about the role of somatostatin-receptors in hepatocellular cancer, and somatostatin analogs have not been investigated for treatment of this malignancy. We present the case of a 68-yr-old male, who was successfully treated with the long-acting somatostatin analog lanreotide.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
January 1994, Oncology reports,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
January 2002, Oncology reports,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
November 2000, The American journal of gastroenterology,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
January 1993, Experimental and clinical endocrinology,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
February 1993, Orvosi hetilap,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
October 1987, The Journal of pediatrics,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
March 2002, Metabolism: clinical and experimental,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
January 1988, Archivos de investigacion medica,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
May 1979, Diabetes,
M Raderer, and M H Hejna, and A Kurtaran, and G V Kornek, and J B Valencak, and G Oberhuber, and F Vorbeck, and I Virgolini, and W Scheithauer
August 2000, American journal of clinical oncology,
Copied contents to your clipboard!